Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VaxGen Inc.-The 1st AIDS Vaccine in Phase 3 HumanTrials -- Ignore unavailable to you. Want to Upgrade?

To: EmuGreg who wrote (63)	7/6/1999 8:11:00 PM
From: GPSite	Read Replies (1) \| Respond to of 250

E.G., It seems to me that there should be quite a few VG releases despite the double-blind study. This is because the general public (and even the institutions) are unaware of what is going on here. This is an AIDS vaccine. It is in phase III trials. Now that VG is a public company they will have a fiduciary responsibility to shareholers to make clear to the public the attractiveness of this investment opportunity. By necessity that will call for PR. However, you are right. Germane references to the nitty-gritty of a phase III study are nonexistent because of the nature of the beast: science demands that results remain unknown until the data are examined. But if you read the prospectus of any phase III company carefully you can pick out the sections that describe when the data might be "broken down early;" in other words, there are provisions to cease the study if it is clear (to an unbiased third agency) that the benefits of the phase III study are statistically signifigant. In that case the study can be halted early and the treatment begun, and then the press is free and easy. GPS